Drug-eluting balloon (DEB) and drug-eluting stent (DES) have been proposed for the treatment of infrapopliteal artery disease. We performed a systematic review and meta-analysis of the current available studies investigating outcomes of DEB and DES in the treatment of infrapopliteal artery disease.
Methods:
Multiple databases were systematically searched to identify studies investigating the outcomes of DEB and DES in the treatment of patients with infrapopliteal artery disease. The quality of studies was assessed by Cochrane Collaboration method. The demographic data, risk factors, outcomes, and antiplatelet strategy were extracted.
Results:
Nine studies were identified with 707 and 606 patients in DEB/DES and standard percutaneous balloon angioplasty (PTA)/bare metal stenting (BMS) group, respectively. The risk of target lesion revascularization (TLR; odds ratio [OR] = 0.38, 95% confidence interval [CI]: 0.23-0.63, P < .01), restenosis rate (OR = 0.30, 95% CI: 0.18-0.50, P < .01), and amputation rate (OR = 0.49, 95% CI: 0.29-0.83, P < .01) significantly decreased in the DES group. The overall survival (OR = 0.86, 95% CI: 0.56-1.32, P = .50) was similar in DES and standard PTA/BMS group; TLR (OR = 0.59, 95% CI: 0.32-1.09, P = .09), restenosis rate (OR = 0.49, 95% CI: 0.11-2.14, P = .35), amputation rate (OR = 1.32, 95% CI: 0.51-3.40, P = .57), and overall survival (OR = 1.40, 95% CI: 0.72-2.71, P = .32) were similar in DEB and standard PTA group.
Conclusion:
The present meta-analysis suggests that compared with standard PTA/BMS, DES may decrease the risk of clinically driven TLR, restenosis rate, and amputation rate without any impact on mortality. However, DEB has no obvious advantage in the treatment of infrapopliteal disease. Due to the limitations of our study, more randomized controlled trials, especially those for DEB, are necessary.
HerringtonWLaceyBSherlikerPArmitageJLewingtonS. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118(4):535–546.
2.
BradburyAWAdamDJBellJ; BASIL Trial Participants. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival prediction model to facilitate clinical decision making. J Vasc Surg. 2010;51(5 suppl):52S–68S.
3.
A prospective epidemiological survey of the natural history of chronic critical leg ischaemia. The I.C.A.I. Group (gruppo di studio dell’ischemia cronica critica degli arti inferiori). Eur J Vasc Endovasc Surg. 1996;11(1):112–120.
4.
van OverhagenHSpiliopoulosSTsetisD. Below-the-knee interventions. Cardiovasc Intervent Radiol. 2013;36(2):302–311.
5.
RomitiMAlbersMBrochado-NetoFCDurazzoAEPereiraCADe LucciaN. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47(5):975–981.
6.
IidaOSogaYKawasakiD. Angiographic restenosis and its clinical impact after infrapopliteal angioplasty. Eur J Vasc Endovasc Surg. 2012;44(4):425–431.
7.
LydenSPSmouseHB. TASC II and the endovascular management of infrainguinal disease. J Endovasc Ther. 2009;16(2 suppl 2):II5–II18.
8.
MohlerEIIIGiriJ; ACC; AHA. Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Curr Med Res Opin. 2008;24(9):2509–2522.
9.
IqbalJGunnJSerruysPW. Coronary stents: historical development, current status and future directions. Br Med Bull. 2013;106:193–211.
10.
Biondi-ZoccaiGGSangiorgiGLotrionteM. Infragenicular stent implantation for below-the-knee atherosclerotic disease: clinical evidence from an international collaborative meta-analysis on 640 patients. J Endovasc Ther. 2009;16(3):251–260.
ScheinertDKatsanosKZellerT; ACHILLES Investigators. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60(22):2290–2295.
13.
TepeGSchmehlJHellerS. Drug eluting stents versus PTA with GP IIb/IIIa blockade below the knee in patients with current ulcers—The BELOW Study. J Cardiovasc Surg (Torino). 2010;51(2):203–212.
14.
BosiersMScheinertDPeetersP. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55(2):390–398.
15.
FalkowskiAPoncyljuszWWilkGSzczerbo-TrojanowskaM. The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries. Eur Radiol. 2009;19(4):966–974.
16.
RastanATepeGKrankenbergH. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32(18):2274–2281.
17.
SpreenMIMartensJMHansenBE. Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia (PADI) trial. Circ Cardiovasc Interv. 2016;9(2):e002376.
18.
ZellerTBaumgartnerIScheinertD; IN.PACT DEEP Trial Investigators. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64(15):1568–1576.
19.
LiistroFPortoIAngioliP. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128(6):615–621.
20.
ZellerTBeschornerUPilgerE. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8(12):1614–1622.
21.
SchillingerMExnerMMlekuschW. Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level. Radiology. 2003;227(2):419–425.
22.
LöfbergAMLöreliusLEKaracagilSWestmanBAlmgrenBBerqgvistD. The use of below-knee percutaneous transluminal angioplasty in arterial occlusive disease causing chronic critical limb ischemia. Cardiovasc Intervent Radiol. 1996;19(5):317–322.
23.
FeiringAJWesolowskiAALadeS. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. J Am Coll Cardiol. 2004;44(12):2307–2314.
24.
PeregrinJHSmírováSKoznarB. Self-expandable stent placement in infrapopliteal arteries after unsuccessful angioplasty failure: one-year follow-up. Cardiovasc Intervent Radiol. 2008;31(5):860–864.
25.
RandTBasileACejnaM. PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study. Cardiovasc Intervent Radiol. 2006;29(1):29–38.
26.
DonasKPTorselloGSchwindtASchönefeldEBoldtOPitouliasGA. Below knee bare nitinol stent placement in high-risk patients with critical limb ischemia is still durable after 24 months of follow-up. J Vasc Surg. 2010;52(2):356–361.
27.
KarnabatidisDSpiliopoulosSKatsanosKSiablisD. Below-the-knee drug-eluting stents and drug-coated balloons. Expert Rev Med Devices. 2012;9(1):85–94.
28.
WallaceELAbdel-LatifACharnigoR. Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109(7):932–940.
29.
FeiringAJKrahnMNelsonLWesolowskiAEastwoodDSzaboA. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial. J Am Coll Cardiol. 2010;55(15):1580–1589.
30.
FusaroMCasseseSNdrepepaG. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. JACC Cardiovasc Interv. 2013;6(12):1284–1293.
31.
AntoniouGAChalmersNKanesalinghamK. Meta-analysis of outcomes of endovascular treatment of infrapopliteal occlusive disease with drug-eluting stents. J Endovasc Ther. 2013;20(2):131–144.
32.
ThomasSDMcdonaldRRVarcoeRL. Vasculitis resulting from a superficial femoral artery angioplasty with a paclitaxel-eluting balloon. J Vasc Surg. 2014;59(2):520–523.
33.
HeldmanAWChengLJenkinsGM. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103(18):2289–2295.
34.
RhaSWChenKYOhDJ. Impact of heterogeneous overlapping drug-eluting stents on the arterial responses of rabbit iliac arteries: a comparison with overlapping bare metal stents. Korean Circ J. 2012;42(6):397–405.
35.
ZhaoHQNikanorovAVirmaniRSchwartzLB. Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus. J Vasc Surg. 2012;56(6):1680–1688.
36.
WilsonGJNakazawaGSchwartzRS. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009;120(2):141–149, 1–2.
37.
LeeCWAhnJMParkDW. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129(3):304–312.
